Literature DB >> 10024846

[Dose-response relation: relevance for clinical practice].

U Klinkhardt1, S Harder.   

Abstract

Dose-finding studies are performed routinely in patients and--if appropriate surrogate models exist--also in healthy volunteers. Such studies aim at establishing the optimal dose range for further clinical studies on the efficacy and the risk-benefit ratio of a new drug. The dose-response relationship of a drug is most often described by a sigmoidal curve. Its parameters include the mean effective dose, the maximal effect and the steepness. Interpretation of such curves should be done in the context of the intended clinical indications of the drug. The risk-benefit ratio of a drug can be assessed by overlapping the dose-response curve of wanted and unwanted clinical effects, again, any overlapping (which can be described e.g. by the therapeutic index) should be seen in the context of the indication and available therapeutic alternatives.

Entities:  

Mesh:

Year:  1998        PMID: 10024846     DOI: 10.1007/bf03044815

Source DB:  PubMed          Journal:  Med Klin (Munich)        ISSN: 0723-5003


  10 in total

Review 1.  Valsartan. A review of its pharmacology and therapeutic use in essential hypertension.

Authors:  A Markham; K L Goa
Journal:  Drugs       Date:  1997-08       Impact factor: 9.546

2.  Dose-finding studies in clinical drug development.

Authors:  R Schmidt
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

3.  How much drug in the tablet?

Authors:  A Herxheimer
Journal:  Lancet       Date:  1991-02-09       Impact factor: 79.321

4.  Prescription of cardiovascular drugs in outpatient care: a survey of outpatients in a German university hospital.

Authors:  S Harder; P Thürmann; C Thierolf; H Klepzig
Journal:  Int J Clin Pharmacol Ther       Date:  1998-04       Impact factor: 1.366

5.  Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension.

Authors:  J L Pool; R M Guthrie; T W Littlejohn; P Raskin; A M Shephard; M A Weber; M R Weir; T W Wilson; J Wright; K B Kassler-Taub; R A Reeves
Journal:  Am J Hypertens       Date:  1998-04       Impact factor: 2.689

6.  Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect.

Authors:  D Elmfeldt; M George; R Hübner; B Olofsson
Journal:  J Hum Hypertens       Date:  1997-09       Impact factor: 3.012

7.  Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects.

Authors:  J E Carlsen; L Køber; C Torp-Pedersen; P Johansen
Journal:  BMJ       Date:  1990-04-14

8.  Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans.

Authors:  J Dingemanse; K M Jorga; M Schmitt; R Gieschke; B Fotteler; G Zürcher; M Da Prada; P van Brummelen
Journal:  Clin Pharmacol Ther       Date:  1995-05       Impact factor: 6.875

Review 9.  A guide to the pharmacology of placebos.

Authors:  C W Gowdey
Journal:  Can Med Assoc J       Date:  1983-04-15       Impact factor: 8.262

10.  Study designs for dose-ranging.

Authors:  L B Sheiner; S L Beal; N C Sambol
Journal:  Clin Pharmacol Ther       Date:  1989-07       Impact factor: 6.875

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.